These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20074477)

  • 1. Bevacizumab-related osteneocrosis of the jaw.
    Serra E; Paolantonio M; Spoto G; Mastrangelo F; Tetè S; Dolci M
    Int J Immunopathol Pharmacol; 2009; 22(4):1121-3. PubMed ID: 20074477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis after administration of intravitreous bevacizumab.
    Hopp RN; Pucci J; Santos-Silva AR; Jorge J
    J Oral Maxillofac Surg; 2012 Mar; 70(3):632-5. PubMed ID: 21757280
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteonecrosis of the jaws and bevacizumab therapy: a case report.
    Brunamonti Binello P; Bandelloni R; Labanca M; Buffoli B; Rezzani R; Rodella LF
    Int J Immunopathol Pharmacol; 2012; 25(3):789-91. PubMed ID: 23058032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
    Francini F; Pascucci A; Francini E; Miano ST; Bargagli G; Ruggiero G; Petrioli R
    J Am Dent Assoc; 2011 May; 142(5):506-13. PubMed ID: 21531932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteonecrosis of the jaw related to bevacizumab.
    Estilo CL; Fornier M; Farooki A; Carlson D; Bohle G; Huryn JM
    J Clin Oncol; 2008 Aug; 26(24):4037-8. PubMed ID: 18711196
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
    Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
    Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab, sunitinib: osteonecrosis of the jaw.
    Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
    [No Abstract]   [Full Text] [Related]  

  • 9. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit.
    Dişel U; Beşen AA; Özyılkan Ö; Er E; Canpolat T
    Oral Oncol; 2012 Feb; 48(2):e2-3. PubMed ID: 21865077
    [No Abstract]   [Full Text] [Related]  

  • 10. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
    Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of osteonecrosis of the jaw during treatment by bevacizumab for sigmoid colon cancer].
    Sato M; Ono F; Yamamura A; Onochi S
    Nihon Shokakibyo Gakkai Zasshi; 2013 Apr; 110(4):655-9. PubMed ID: 23558129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jaw and bevacizumab therapy.
    Van Poznak C
    Breast Cancer Res Treat; 2010 Jul; 122(1):189-91. PubMed ID: 20464477
    [No Abstract]   [Full Text] [Related]  

  • 13. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
    Gallego L; Junquera L
    Br J Oral Maxillofac Surg; 2009 Jan; 47(1):67-8. PubMed ID: 18639371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
    Sivolella S; Lumachi F; Stellini E; Favero L
    Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2011; 59(6):410-3. PubMed ID: 22313910
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
    Merigo E; Manfredi M; Meleti M; Guidotti R; Ripasarti A; Zanzucchi E; D'Aleo P; Corradi D; Corcione L; Sesenna E; Ferrari S; Poli T; Bonaninil M; Vescovi P
    Acta Biomed; 2006 Aug; 77(2):109-17. PubMed ID: 17172192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab-associated osteonecrosis of the jaw.
    Greuter S; Schmid F; Ruhstaller T; Thuerlimann B
    Ann Oncol; 2008 Dec; 19(12):2091-2. PubMed ID: 18977851
    [No Abstract]   [Full Text] [Related]  

  • 18. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the mandible associated with bevacizumab therapy.
    Santos-Silva AR; Belizário Rosa GA; Castro Júnior Gd; Dias RB; Prado Ribeiro AC; Brandão TB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Jun; 115(6):e32-6. PubMed ID: 23567260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
    Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
    J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.